2016 LAM Foundation International Lymphangioleiomyomatosis Research Conference

2016年LAM基金会国际淋巴管平滑肌瘤病研究会议

• 批准号: 9195335
• 负责人: Francis Xavier McCormack
• 金额: $ 2.5万
• 依托单位: UNIVERSITY OF CINCINNATI
• 依托单位国家: 美国
• 财政年份: 2008
• 资助国家: 美国
• 起止时间: 2008-04-04 至 2017-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9195335
• 关键词: Abdomen; Address; Adopted; Age; Angiomyolipoma; Australia; Award; Basic Science; Biological Markers; Biology; Blood Vessels; Caring; Chest; Chronic; Clinic; Clinical; Clinical Investigator; Clinical Management; Clinical Sciences; Clinical Treatment; Collection; Communities; Complement; Complex; Conscious; Consensus; Country; Diagnosis; Diffuse; Discipline; Disease; Dissection; Distal; Doctor of Philosophy; Double-Blind Method; Drosophila genus; Dyspnea; Endocrinology; European Union; Evaluation; Evolution; Exertion; FDA approved; FRAP1 gene; Family; Family member; Fibrosis; Foundations; Funding; Genes; Goals; Grant; Hemoptysis; Hereditary Disease; High Resolution Computed Tomography; Image; Immunity; Infiltration; Inherited; International; Interstitial Lung Diseases; Japan; Kidney Neoplasms; Laboratories; Learning; Life; Liquid substance; Lung; Lung Transplantation; Lung diseases; Lymphangiogenesis; Lymphangioleiomyomatosis; Lymphangiomyoma; Lymphatic; Matrix Metalloproteinases; Measures; Memory; Mind; Molecular; Molecular Target; Molecular and Cellular Biology; National Heart, Lung, and Blood Institute; Pathology; Pathway interactions; Patient Participation; Patients; Phase I/II Trial; Phenotype; Physicians; Pleural Diseases; Pneumothorax; Quality of life; Radiology Specialty; Randomized; Recording of previous events; Recurrence; Reporting; Research; Research Design; Research Personnel; Respiratory physiology; Role; Russia; Scientist; Series; Signal Transduction; Sirolimus; Smooth Muscle; Smooth Muscle Myocytes; Smooth Muscle Tumor; South Korea; Structure; TSC2 gene; Time; Transplantation; Travel; Tuberous Sclerosis; Tuberous sclerosis protein complex; Ultrasonography; United States National Institutes of Health; Woman; Work; X-Ray Computed Tomography; abstracting; airway obstruction; alveolar destruction; base; bench to bedside; biomarker development; cell growth; clinical investigation; gene product; improved; innovation; lymph nodes; mTOR Inhibitor; meetings; multidisciplinary; patient oriented; posters; programs; research and development; respiratory; symposium; teacher; treatment trial

ABSTRACT The 2016 LAM Foundation International Lymphangioleiomyomatosis Research Conference will focus on the molecular mechanisms of smooth muscle proliferation and cystic lung destruction that occur in the fatal lung disease of women, Lymphangioleiomyomatosis (LAM). This is the nineteenth annual LAM conference, which has evolved from a dedicated family/patient conference to a state of the art scientific meeting for LAM and tuberous sclerosis. The 2016 meeting will be held in Cincinnati, in parallel with the Rare Lung Disease Conference. The basic science sessions will focus on lymphangiogenesis and lymphatic imaging, mTOR signaling, LAM biomarkers and patient centered research designs. More clinically oriented talks will be incorporated into most sessions, to address practical challenges regarding treatment of the disease, issues unique to transplantation of LAM patients and the development of biomarkers and phenotyping approaches for LAM following lessons learned from other diseases. A concurrent patient-oriented seminar series will address key clinical issues for 280 LAM patients and LAM family members who are expected to attend, and will culminate in a summary of scientific sessions by the Basic and Clinical Track Chairs. A half day LAM Foundation Clinic Directors meeting will be convened on the last day of the conference to discuss challenging cases, and set priorities for the network. Each session will be chaired by an expert in the field and will have invited speakers as well as speakers chosen from the pool of submitted abstracts. There has been a conscious effort to attract established investigators from related disciplines who can complement the expertise of the current pool of LAM investigators. Discussion facilitated by a discussion leader will be an important component of all sessions. Outstanding junior investigators will be awarded travel grants based on merit and will be given the opportunity to present their research in platform and poster formats. The goal of this conference is to provide a forum for leading experts to discuss the molecular and cellular basis of LAM, review the clinical management of LAM, to present cutting edge research, to integrate concepts and to identify creative and innovative research directions.

摘要 2016年LAM基金会国际淋巴管平滑肌瘤病研究会议将重点关注 致死性肺中平滑肌增殖和囊性肺破坏的分子机制 淋巴管平滑肌瘤病（Lymphangioleiomyomatosis，LAM）这是第十九届年度LAM会议， 已经从一个专门的家庭/患者会议发展成为一个最先进的LAM科学会议， 结节性硬化症2016年的会议将在辛辛那提举行，与罕见肺病会议同时举行。 会议基础科学会议将集中在淋巴管生成和淋巴成像，mTOR 信号传导、LAM生物标志物和以患者为中心的研究设计。更多的临床导向的会谈将是 纳入大多数会议，以解决有关疾病治疗的实际挑战， 独特的LAM患者移植和生物标志物和表型方法的发展， LAM从其他疾病中吸取了教训。同时举行的以病人为导向的系列研讨会将讨论 为280名预计参加的LAM患者和LAM家庭成员提供关键临床问题，并将 最后由基础和临床跟踪主席总结科学会议。半天林 基金会诊所主任会议将在会议的最后一天召开，讨论具有挑战性的 #21453;，并为网络设置优先级。每届会议将由该领域的一名专家主持， 邀请的发言者以及从提交的摘要库中选出的发言者。有一种意识 努力吸引相关学科的资深调查员，他们可以补充联合国的专门知识， 目前的LAM研究人员库。由讨论带头人主持的讨论将是一个重要组成部分 所有会议。优秀的初级调查员将根据成绩获得旅费赠款， 有机会以平台和海报的形式展示他们的研究。本次会议的目标是 为领先的专家提供一个论坛，讨论LAM的分子和细胞基础，审查临床 LAM的管理，提出前沿研究，整合概念，并确定创造性和 创新的研究方向。